Clinical Trial Update: An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects [Phase 3]

View source ↗

Summary

An open-label extension study assessed the safety and tolerability of perampanel as an adjunctive therapy for epilepsy; the Phase 3 trial is completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Fycompa (perampanel)

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2018-07-02